Close Menu

BARCELONA – Researchers from the Zhejiang Cancer Hospital in Hangzhou, China have found what they believe could be a DNA methylation signature predictive of central nervous system metastases in patients with advanced non-small cell lung cancer (NSCLC).

In a presentation at the annual meeting of the European Society for Medical Oncology in Barcelona on Friday, Zheijang researcher Yanjun Xu reported her group's work in analyzing DNA mutations and methylation to find possible biomarkers of lung cancer metastasis to the brain or the leptomeninges.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Mar
23
Sponsored by
Roche

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.